Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2011 Mar;96(3):e12-3; author reply e14.
doi: 10.3324/haematol.2010.038414.

Erythropoietin receptor is detectable on peripheral blood lymphocytes and its expression increases in activated T lymphocytes

Katarzyna A Lisowska, Ewa Bryl, Jacek M Witkowski
Comment

Erythropoietin receptor is detectable on peripheral blood lymphocytes and its expression increases in activated T lymphocytes

Katarzyna A Lisowska et al. Haematologica. 2011 Mar.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
EPO-R expression on CD4+ T lymphocytes ex vivo (A) and CD4+ and CD4+ T lymphocytes stimulated with immobilized anti-CD3 antibody. (B) Figure shows representative 2 flow cytometry histograms for 30 experiments yielding similar results. EPO-R expression (black line) was estimated as a mean fluorescence shift toward control unstained with anti-EpoR monoclonal antibody (gray field), P<0.05, Kolmogorov-Smirnov test. Number of EPO-R was calculated using Phycoerythrin Fluorescence Quantitation Kit (Becton Dickinson, USA) according to the manufacturer’s protocol.
See this image and copyright information in PMC

Comment on

  • Macrophages as novel target cells for erythropoietin.
    Lifshitz L, Tabak G, Gassmann M, Mittelman M, Neumann D. Lifshitz L, et al. Haematologica. 2010 Nov;95(11):1823-31. doi: 10.3324/haematol.2010.025015. Epub 2010 Jun 30. Haematologica. 2010. PMID: 20595096 Free PMC article.

References

    1. Lifshitz L, Tabak G, Mittelman M, Gassmann M, Neumann D. Macrophages as novel targets for erythropoietin. Haematologica. 2010;95(11):1823–40. - PMC - PubMed
    1. Prutchi-Sagiv S, Golishevsky N, Oster HS, Katz O, Cohen A, Naparstek E, et al. Erythropoietin treatment in advanced multiple myeloma is associated with improved immunological functions: could it be beneficial in early disease? Br J Haematol. 2006;135(5):660–72. - PubMed
    1. Sela S, Shurtz-Swirski R, Sharon R, Manaster J, Chezar J, Shkolnik G, et al. The polymorphonuclear leukocyte--a new target for erythropoietin. Nephron. 2001;88(3):205–10. - PubMed
    1. Bryl E, Mysliwska J, Debska-Slizien A, Trzonkowski P, Rachon D, Bullo B, et al. Recombinant human erythropoietin stimulates production of interleukin 2 by whole blood cell cultures of hemodialysis patients. Artif Organs. 1999;23(9):809–16. - PubMed
    1. Bryl E, Mysliwska J, Debska-Slizien A, Rachon D, Bullo B, Lizakowski S, et al. The influence of recombinant human erythropoietin on tumor necrosis factor alpha and interleukin-10 production by whole blood cell cultures in hemodialysis patients. Artif Organs. 1998;22(3):177–81. - PubMed

MeSH terms